Clinical Trial Update: Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain [Phase 4]

View source ↗

Summary

Phase 4 trial investigating hypotonic treprostinil subcutaneous infusion for control of site pain related to treprostinil; the study has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Treprostinil (treprostinil)
• hypotonic treprostinil subcutaneous infusion

Snippet

Sponsor: Jewish General Hospital | Conditions: Pulmonary Arterial Hypertension | Phase 4 | Status: WITHDRAWN